These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 8811491)

  • 1. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.
    Wojtowicz-Praga S; Verma UN; Wakefield L; Esteban JM; Hartmann D; Mazumder A
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):169-75. PubMed ID: 8811491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice.
    Gridley DS; Sura SS; Uhm JR; Lin CH; Kettering JD
    Cancer Biother; 1993; 8(2):159-70. PubMed ID: 7804355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
    Courtney LP; Phelps JL; Karavodin LM
    Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.
    Bonnekoh B; Greenhalgh DA; Chen SH; Block A; Rich SS; Krieg T; Woo SL; Roop DR
    J Invest Dermatol; 1998 Jun; 110(6):867-71. PubMed ID: 9620291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
    Mao XW; Kettering JD; Gridley DS
    Cancer Biother; 1994; 9(4):317-27. PubMed ID: 7719379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.
    Jiang J; Zhang Y; Peng K; Wang Q; Hong X; Li H; Fan G; Zhang Z; Gong T; Sun X
    Acta Biomater; 2017 Oct; 61():114-123. PubMed ID: 28483693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour.
    Neville ME; Pezzella KM
    Cytokine; 1994 May; 6(3):310-7. PubMed ID: 8054488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6.
    Mckenzie RC; Park ES; Brown WR; Shivji GS; Sauder DN
    Photodermatol Photoimmunol Photomed; 1994 Apr; 10(2):74-9. PubMed ID: 8043388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
    Seo N; Hayakawa S; Takigawa M; Tokura Y
    Immunology; 2001 Aug; 103(4):449-57. PubMed ID: 11529935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model.
    Shrayer D; Koness J; Kouttab N; Bogaars H; Hearing VJ; Gersten DM; Maizel A; Wanebo H
    J Surg Oncol; 1993 Mar; 52(3):142-9. PubMed ID: 8441268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.
    Patel D; Bassi R; Hooper AT; Sun H; Huber J; Hicklin DJ; Kang X
    Anticancer Res; 2008; 28(5A):2679-86. PubMed ID: 19035294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.
    Cao X; Zhang W; Gu S; Yu Y; Tao Q; Ye T
    J Cancer Res Clin Oncol; 1995; 121(12):721-8. PubMed ID: 7499443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
    Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
    Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.
    Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; Berraondo P; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
    Int J Cancer; 2009 Dec; 125(11):2614-23. PubMed ID: 19530254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
    Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
    Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
    Eisenthal A; Cameron RB; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.